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1 Introduction
1.1 The International Pharmacopoeia
1.1.1 Definition
The  International  Pharmacopoeia  (Ph.  Int.)  is  published  by  the  World  Health 
Organization (WHO) and per definitionem “(...) comprises a collection of recommended 
procedures  for  analysis  and  specifications  for  the  determination  of  pharmaceutical 
substances, excipients and dosage forms that is intended to serve as source material for 
reference or adaptation by any WHO Member State wishing to establish pharmaceutical 
requirements.” [The International Pharmacopoeia, 4th edition]
1.1.2 History
The history of the Ph. Int. can be tracked back to the year 1874, when the necessity of 
standardized terminology and specified drug composition was recognized. Different steps 
in this development, like the  Agreement for the Unification of the Formulae of Potent 
Drugs (1902) and the Brussels Agreement (1925) in turn led to the constitution of an 
Expert Committee on the Unification of Pharmacopoeias by the Interim Commission of 
the  WHO,  the  aim of  which  was  to  produce  a  draft  international  agreement  for  the 
unification  of  pharmacopoeias,  continuing  the  work  previously  undertaken  in  this 
direction.  In  1951 this  committee  became the Expert  Committee  on the International 
Pharmacopoeia and the first edition of the Ph. Int. was published in two volumes (1951 
and 1955).
In 1967 the second edition was published, which, taking into account the development of 
new analytical  techniques,  revised  the  first  edition,  making  numerous  alterations  and 
adding new analytical methods.
In 1975 the purpose of the Ph. Int. was reconsidered, putting the focus on the needs of 
developing countries and using simple classical chemical techniques in order to make the 
pharmacopoeia applicable also in laboratories without expensive equipment. Priority was 
henceforward given to drugs that are widely used throughout the world, part of WHO 
health  programmes or likely to contain impurities due to degradation or difficulties in 
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their manufacturing process. Since 1979 the drugs included in the Ph. Int. have been 
selected from the WHO List of Essential Drugs.
The fourth and latest edition of the Ph. Int. was published in two volumes in 2006. It was 
updated  by  a  first  supplement  in  2008  and  a  second  one  in  2011,  which  added 
monographs  for  pharmaceutical  substances  as  well  as  dosage  forms,  mainly  for 
antiretroviral,  antimalarial,  antituberculosis  and  anti-infectives  medicines  [The
International Pharmacopoeia, 4th edition].
1.1.3 Intention
The aim of the Ph. Int. is to promote the overall quality of pharmaceutical substances and 
dosage forms. It contains quality specifications which are intended as basic requirements 
for pharmaceutical products and serve as source material for establishing pharmaceutical 
standards  throughout  the  world.  Therefore,  it  focuses  on  states  that  do  not  have 
pharmacopoeial compendia of their own, i.e. developing countries. 
The Ph. Int. provides information on general requirements for pharmaceutical products 
and methods of analysis. In an attempt to minimize the use of expensive equipment it 
focuses on simple classical techniques. More sophisticated methods are included as well 
but usually accompanied by an alternative, less complex method. It contains monographs 
on  drug  substances  and  dosage  forms.  The  latest  version  covers  monographs  on  the 
following categories:
• HIV/AIDS 
• Malaria
• Tuberculosis
• Anti-Infective 
• Oral Rehydration therapy 
• Radiopharmaceuticals
• Other medicines 
The selection of monographs for inclusion in the Ph. Int. is based on the current WHO 
Model List of Essential Medicines and takes WHO disease programs into account  [The
International Pharmacopoeia, 4th edition].
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1.2 The WHO Model List of Essential Medicines
The WHO Model List of Essential Medicines (formerly known as WHO list of essential 
drugs) is a compendium of medicines which “satisfy the priority health care needs of a 
population.  They are selected with regard to disease prevalence,  evidence of efficacy, 
safety, and comparative cost-effectiveness”.
Since the development of the first list in 1977 it has been updated every two years. The 
latest  version  (March  2011)  lists  over  350  medicines  for  the  treatment  of  priority 
conditions, such as HIV/AIDS, malaria, tuberculosis and reproductive health as well as 
chronic  diseases  like  cancer  and  diabetes.  Its  purpose  is  to  serve  as  a  guide  for 
establishing national essential medicines lists, which take local and regional needs into 
account. Especially in countries with less functional health systems it is supposed to help 
identify suitable medicines for priority health issues and thereby improve availability, 
accessibility, affordability and quality of essential drugs.
In 2007, a WHO Model List of Essential Medicines for Children was developed, which 
has also been updated every two years [WHO Factsheet Essential Medicines].
1.3 HIV/ AIDS
1.3.1 Overview
The occurrence of an acquired immunodeficiency syndrome (AIDS) was first described 
in 1981. A novel human retrovirus was isolated in 1983, soon identified as etiological 
agent and eventually named HIV  [Sepkowitz 2001].  Human immunodeficiency viruses 
(HIV) are lentiviruses, a family of mammalian retroviruses. Its natural hosts are humans 
and nonhuman primates. It causes chronic persistent infections and progressively reduces 
the effectiveness of the immune system by destroying CD4+ T-helper cells. This in turn 
leads to an increasing susceptibility for opportunistic infections, which is called AIDS 
[Hare 2006].
There are two major groups of HIV: HIV-1, which is involved in most of the pandemic,  
and HIV-2, which is more closely related to the simian immunodeficiency virus (SIV) 
and occurs mostly in western Africa. Both of these groups can further be divided into 
subgroups, depending on their genomic sequence [HIV Sequence Database].
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According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), almost 60 
million people have been infected since the beginning of the epidemic and 25 million 
people have died of HIV-related causes [UNAIDS Global facts and figures 09].
The latest  WHO global summary lists 2.6 million people newly infected with HIV in 
2009, who add to a total of 33.3 million people living with HIV, about 97% of whom live 
in low or middle income countries [WHO Global summary of the AIDS epidemic 2009].
1.3.1.1 Characteristics of HIV
1.3.1.1.1 Structure
HIV consists of an RNA genome of 9300 base pairs, two copies of which are contained 
in a nucleocapsid core surrounded by a lipid bilayer envelope that is derived from the 
host  cell's  plasma  membrane  (Figure  1).  The  genome  consists  of  nine  genes  which 
encode 15 proteins. The three most important are gag, which encodes the major structural 
proteins  of  the  virus,  pol, which  encodes  viral  enzymes  like  integrase,  protease  and 
reverse transcriptase (RT), and  env, which encodes the large transmembrane envelope 
protein.  Nef,  rev,  tat,  vif,  vpr,  vpu encode  regulatory  proteins  that  enhance  virion 
production or antagonise host defenses. The viral particle also contains enzymes essential 
for the viral development such as integrase, protease and RT [Greene and Peterlin 2002].
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Figure 1: Schematic picture of an HIV virion
1.3.1.1.2 Life Cycle
HIV infects lymphocytes and macrophages that express the cluster of differentiation 4 
glycoprotein  (CD4)  on  their  surface.  The  tropism for  these  cells  is  mediated  by  the 
envelope protein (env). Cell entry also requires binding to a coreceptor,  generally the 
chemokine  receptor  CCR5  or  CXCR4  [Greene  and  Peterlin  2002].  While  CCR5  is 
present  on  macrophage  lineage  cells,  CXCR4 is  found on T-lymphocytes.  HIV with 
CCR5-tropism is responsible for most of the naturally acquired infections, whereas a shift 
to CXCR4 tropism is usually associated with advancing disease and resulting in a higher 
affinity  for  CXCR4,  infection  of  T-Lymphocytes  and  increased  risk  for 
immunosuppression [Berger et al. 1999].
HIV binds to the CD4 receptor and the coreceptor on the cell surface with its surface 
gp120 protein, which induces a conformational change and exposition of the gp41 protein 
which  penetrates  the  target  cell  membrane  and  promotes  fusion  of   virus  and  cell 
membrane.  After  entry of  the  viral  capsid  uncoating  takes  place  and viral  RNA and 
various enzymes are released. The reverse transcription complex is formed and, based on 
the viral RNA, a complementary DNA (cDNA) strand is produced, mediated by RT. The 
original RNA strand is degraded, allowing the creation of a double-stranded DNA copy 
of  the  virus.  After  completion  of  the  reverse  transcription,  a  preintegration  complex 
containing the double-stranded viral DNA enters the cell nucleus, where it is inserted into 
the host genome by integrase. This provirus can remain latent, not producing new virions 
but replicating as the cell divides or it can be transcriptionally active, depending on the 
chromosomal milieu in which it  is  integrated.  However,  if  more than one provirus is 
established in one cell, it is very likely that at least one is transcriptionally active. In the 
latter case it uses the host cell to produce viral RNA and proteins. 
Structural  viral  proteins  and  RNA  assemble  within  the  cytoplasm  to  form  new 
nucleocapsids whereas viral envelope proteins assemble at cholesterol rich lipid rafts at 
the cell surface. The capsid cores are then directed to those sites and bud through the cell 
membrane to form new virions [Goodman & Gilman's 2011].
A schematic replicate circle of HIV is given in Figure 2.
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1.3.1.2 HIV-Infection and development of AIDS
HIV  can  be  transmitted  through  unprotected  sexual  intercourse,  transfusion  of 
contaminated blood, sharing of contaminated needles or between a mother and her infant 
during pregnancy, childbirth and breastfeeding.
Infection is followed by a burst in viral replication peaking after 2-4 weeks, which is 
associated with a massive decrease of the number of CD4+ T-lymphocytes and in most 
cases accompanied by influenza or a mononucleosis-like illness (Acute HIV infection) 
[Kahn and Walker 1998].
Symptoms of these usually vanish after 4 weeks as the plasma HIV RNA concentration 
declines, as a result of new host immune responses and depletion of target cells. The viral 
load reaches a quasi steady state which reflects the interaction between pathogenicity of 
HIV and host immunity (Chronic HIV infection). Eventually, the number of host CD4+ 
T-lymphocytes  begin a  steady decrease,  whereas  the plasma HIV concentration rises. 
Once the CD4 cell count falls below a threshold of 200 cell/µl, the risk of opportunistic  
infections increases [Goodman & Gilman's 2011]. 
Untreated, infection with HIV usually leads to clinical manifestation of AIDS within 5-10 
years.
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Figure 2: Replicate circle of HIV-1 showing the sites of action of available antiretroviral agents,  
from [Goodman & Gilman's 2011]
RT, reverse transcriptase; cDNA, complementary DNA; mRNA, messenger RNA; Rnase H,  
ribonuclease H; gp160+gp41, envelope glycoprotein.
The WHO uses the following classification system to determine the progression of HIV 
infections [WHO Disease Staging System for HIV Infection and Disease]:
• Primary HIV infection -  may be asymptomatic  or experienced as acute 
retroviral syndrome
• Clinical  stage  1  -  asymptomatic  or  generalized  swelling  of  the  lymph 
nodes
• Clinical  stage  2  -  includes  minor  weight  loss,  minor  mucocutaneous
manifestations, and recurrent upper respiratory tract infections
• Clinical  stage  3  -  includes  unexplained  chronic  diarrhoea,  unexplained 
persistent  fever,  oral  candidiasis  or  leukoplakia,  severe  bacterial 
infections, pulmonary tuberculosis, and acute necrotizing inflammation in 
the mouth
• Clinical stage 4 - includes 22 opportunistic infections or cancers related to 
HIV
The criteria used for AIDS diagnosis were established by the US Centers for Disease 
Control  and  Prevention  (CDC)  and  include  the  occurrence  of  any  of  more  than  20 
opportunistic infections or HIV-related cancers.  Also a CD4+ T-cell count below 200 
cells/µl blood is defined as AIDS by the CDC [CDC revised classification system].
1.3.1.3 Treatment of HIV infection
So far,  no  curative  treatment  for  HIV-infection  has  been found.  Therapy focuses  on 
slowing down the progression and delaying the manifestation of AIDS. Current treatment 
is based on the assumption that all aspects of the disease are a result of the HIV on host 
cells,  mainly  CD4+  T-lymphocytes.  Successful  therapy  is  therefore  based  on  the 
inhibition of HIV replication and thereby increasing the levels of CD4+ T-lymphocytes. 
A conceivable positive effect by boosting host immunities, without additive antiretroviral 
remedies has had no reliable clinical benefit [Goodman & Gilman's 2011].
On the other hand, any treatment exerting long-term suppression of virus replication has 
been shown to be beneficial [Lee et al. 2001]. Thus, the credo of HIV-chemotherapy is to 
suppress HIV replication as much as possible for as long as possible.
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An  important  question  in  the  therapy  of  chronic  HIV  infection,  which  has  caused 
extensive discussion, is when to start. Current guidelines by the US Department of Health 
and Human Services  recommend starting in  those patients  with a  CD4 count  of  500 
cells/µl or lower [Department of Health and Human Services 2011]. The European AIDS 
Clinical Society, on the other hand, recommends treatment at a CD4 count of less than 
350 cells/µl and consideration of treatment at CD4 counts of more than 350 cells/µl if 
one  or  more  comorbidities  are  present  [European  Guidelines  for  treatment  of  HIV
infected adults in Europe 2009]. The WHO guidelines, however, recommend  treatment 
of patients with WHO clinical stages 3 and 4 and at CD4 counts of 350 cells/µl or below, 
irrespective  of  the  WHO  clinical  level  [Antiretroviral  Therapy  for  HIV  infection  in
Adults and Adolescents 2010].
However,  increasing  evidence  shows the clinical  benefit  of  starting  therapy at  higher 
CD4 counts, beginning at CD4 counts of 500 cells/µl or lower [Kitahata et al. 2009]. 
In  the  foreseeable  future,  treatment  may be  recommended for  all  infected  adults  and 
children [Flexner 2007]. 
The current standard in therapy of chronic HIV infection is to use a combination of at 
least three drugs simultaneously for the duration of the treatment in order to achieve a 
highly effective antiretroviral effect and prevent HIV drug resistance.  The aim of this 
Highly  Active  Antiretroviral  Therapy  (HAART)  is  to  reduce  the  viral  load  to  an 
undetectable  level  (<50  copies/ml)  within  24  weeks  after  starting  treatment.  This 
treatment  is  effective  against  viral  replication  and infection  of  target  cells,  it  cannot, 
however, eradicate HIV DNA integrated in host chromosomes. Consequently, life-long 
treatment is imperative to keep plasma HIV RNA levels low and inhibit progression of 
infection as well as reduce the risk of transmission.
While  most  antiretroviral  therapy  is  used  in  treatment  of  established  chronic  HIV 
infection,  this  medication  is  also  used  in  short  courses  to  prevent  mother-to-child 
transmissions and infection in post exposure setting [Goodman & Gilman's 2011].
1.3.1.3.1 Challenges in HIV treatment
Treating  HIV infections  faces  a  lot  of  challenges.  One of  the most  prominent  is  the 
prevention of drug resistance. HIV RT lacks a proofreading function and is error prone, 
so mutation is quite frequent.  It  is estimated that  out of every full-length replication, 
mutations occur at approximately three bases [Coffin 1995]. Given the large number of 
replication  cycles  in  infected  patients,  mutations  that  lead  to  the  emergence  of  drug 
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resistance are likely to occur, especially in untreated patients. Therefore, first-line therapy 
uses a combination of at least three antiretroviral agents, with different targets, usually 
two nucleoside/nucleotide RT inhibitors (NRTIs) and one non-nucleoside RT inhibitor 
(NNRTI), protease inhibitor or integrase inhibitor. 
Treatment failure, which is defined as increasing plasma HIV RNA concentrations in a 
patient with a previously undetectable virus, requires a change of treatment, usually the 
implementation of a completely new combination of drugs. It is often the result of non-
adherence, which depends on the percentage of prescribed doses taken, as well as the 
drugs  used  in  the  regimen  [Goodman  &  Gilman's  2011].  In  an  effort  to  improve 
compliance, fixed dosage combinations,  containing multiple antiretroviral agents, have 
been established and most  antiretrovirals  are  administered  orally once or twice daily. 
Enfuvirtide  is  the  only  approved  antiretroviral  drug  that  has  to  be  administered 
parenterally and it is not used for first line therapy [Flexner 2007].
With more effective antiretroviral therapy and increasing life expectancy of HIV patients, 
long-term toxicity  becomes of greater  concern.  A common consequence of long-term 
therapy is the development of HIV lipodystrophy syndrome, which has been observed in 
10-40  per  cent  of  patients  receiving  long-term  treatment.  The  contribution  of  drug 
therapy to an increased cardiovascular risk associated with chronic HIV infection is not 
well defined either [Calmy et al. 2009].
A potential concern that applies to protease inhibitors and NNRTIs is pharmacokinetic 
drug interactions, as all agents of these classes can act as inducers or inhibitors of hepatic 
cytochrome P450 enzymes (CYPs) and other drug metabolizing enzymes  [Goodman &
Gilman's 2011]. A better safety profile will therefore play a more important role in the 
approval of new antiretroviral drugs.
However,  one  of  the  biggest  challenges  in  fighting  the  HIV pandemic  is  to  provide 
antiretroviral  therapy to everyone who needs it.  This is not so much of a problem in 
developed countries, whereas the coverage in antiretroviral therapy in low- and middle 
income-countries is only 36 per cent [WHO, UNICEF, UNAIDS progress report 2009]. 
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1.3.1.3.2 Drugs used to treat HIV infection
1.3.1.3.2.1 Overview
Antiretroviral drugs can rationally be classified according to their viral targets. A large 
number of antiretrovirals target viral replication and the responsible viral enzymes, most 
eminently  RT,  protease  and 
integrase. Inhibitors of RT and 
protease  were  the  first 
available  antiretroviral  drugs 
and  as  per  now,  a  relatively 
large  number  of  drugs  is 
available for both targets. For 
integrase,  on  the  other  hand, 
the  first  and up to  now only 
inhibitor  was  approved  in 
2007.  A  newer  approach 
targets  viral  entry  in  CD4+ 
cells, with two drugs available 
so far.
Further  potential  targets 
include  HIV  regulatory 
proteins  as  well  as  host  cell 
structures,  like  the  CXCR4 
receptor  or  host  proteins 
involved  in  HIV  replication 
and research in that direction 
is  under  way  (Figure  3) 
[Flexner 2007]. 
1.3.1.3.2.2 Reverse transcriptase inhibitors
Inhibitors  of  RT,  which  converts  viral  RNA into  viral  DNA, can be  subdivided into 
nucleoside/nucleotide  reverse  transcriptase  inhibitors  (NRTIs)  and  non-nucleoside 
inhibitors (NNRTIs)
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Figure 3: HIV replication cycle with current and possible targets for  
antiretroviral intervention, from [Flexner 2007]
current targets are blue and  yellow, possible targets are coloured  
red.
 1.3.1.3.2.2.1 Nucleoside /Nucleotide 
reverse transcriptase 
inhibitors
NRTIs  structurally  resemble  natural 
nucleotides.  They  must  enter  cells  and 
undergo  phosphorylation  in  order  to 
present  synthetic  substrates  to  RT.  The 
phosphorylated  analogues  compete  with 
native  nucleotides  for  incorporation  into 
the  nascent  proviral  DNA  and  thereby 
inhibit proper reverse transcription. Due to 
the lack of a 3'-hydroxyl  group they also 
terminate  elongation  [Goodman  &
Gilman's 2011].
Their  selective  toxicity  depends  on  their 
ability to inhibit HIV RT without affecting 
host  cell  DNA polymerases.  While  all  of 
these  drugs  have  low  affinity  to  human 
DNA  polymerases  α  and  β,  some  can 
inhibit  human  DNA  polymerase  γ,  the 
mitochondrial  enzyme.  This  toxicity  can 
cause anemia, granulocytopenia, myopathy, 
peripheral  neuropathy  and  pancreatitis 
[Calmy et al. 2009].
NRTIs are effective against both HIV-1 and 
HIV-2.
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Table 1: List of antiretroviral agents approved for  
use, modified from [Goodman & Gilman's 2011]
 1.3.1.3.2.2.2 Non-nucleoside reverse transcriptase inhibitors
NNRTIs are a structurally varied class of substrates that bind to a hydrophobic pocket in 
the p66 subunit of HIV-1 RT. The pocket is distant from the active site and the NNRTI-
binding is not essential for the enzyme activity. However, the NNRTI binding induces a 
conformational change in the enzyme that greatly decreases its activity. Unlike NRTIs, 
NNRTIs  do  act  as  non  competitive  inhibitors  and  do  not  need  activation  through 
phosphorylation.  Their  binding site however,  is virus-strain-specific  and the approved 
agents  are  only  active  against  HIV-1.  They have  no  activity  against  host  cell  DNA 
polymerases. Frequent side effects include rashes during the first four weeks of treatment 
and fat accumulation after long-term use [Goodman & Gilman's 2011].
1.3.1.3.2.3 HIV protease inhibitors
HIV protease inhibitors are peptidomimetic agents that competitively inhibit the action of 
the  viral  aspartyl  protease,  thus  preventing  proteolytic  cleavage  of  HIV gag  and pol 
precursor polypeptides which include essential structural and enzymatic components, and 
thereby  anticipating  virus  maturation.  Human  aspartyl  proteases  are  not  significantly 
inhibited due to their different structure.
Most  HIV protease  inhibitors  inhibit  CYP 3A4 at  clinically  achieved  concentrations, 
causing  metabolic  drug interactions.  Common side  effects  are  gastrointestinal  effects 
during the first four weeks of treatment and an increased risk of insulin resistance and 
lipodystrophy in the long run [Goodman & Gilman's 2011].
1.3.1.3.2.4 Integrase inhibitors
These agents target  integrase,  the viral  enzyme responsible for integration of proviral 
DNA into the host chromosomes. Integrase is an excellent antiretroviral target, as human 
DNA does not undergo excision and reintegration. Raltegravir, the only approved drug of 
this group, prevents covalent binding between host and viral DNA by interfering with 
essential divalent cations in the catalytic core of the enzyme. It is effective against both 
HIV-1 and HIV-2 and generally well tolerated [Goodman & Gilman's 2011].
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1.3.1.3.2.5 Entry inhibitors
In this category there are currently two approved agents with different mechanisms.
 1.3.1.3.2.5.1 Maraviroc
Maraviroc is a chemokine receptor antagonist and binds to the host cell CCR5 receptor 
and thereby blocks binding of the viral envelope protein gp120. It is the only approved 
antiretroviral drug that targets a host protein. It is effective against CCR5- tropic strains 
of HIV and has no activity against CXCR4- or dual-tropic strains. It is generally well 
tolerated, but there is some theoretical concern that CCR5 inhibition might interfere with 
immune function [Goodman & Gilman's 2011].
 1.3.1.3.2.5.2 Enfuvirtide
Enfuvirtide  is  a  synthetic  peptide  and  inhibits  fusion  of  viral  and  cell  membranes 
mediated by gp41 and CD4-receptors. It binds gp41 and inhibits conformational changes 
essential  for  membrane  fusion.  Its  amino  acid  sequence  is  derived  from  the 
transmembrane  gp41  region  of  HIV-1,  therefore  it  is  only  active  against  HIV-1. 
Enfuvirtide  has  to  be  administered  parenterally.  The  most  common  side  effects  are 
injection-site reactions, like pain and erythema [Goodman & Gilman's 2011].
1.3.2 Drugs used in this study
This  study  deals  with  ritonavir  (RTV),  efavirenz  (EFV),  emtricitabine  (FTC)  and 
tenofovir disoproxil fumarate (TDF).
1.3.2.1 Ritonavir
Ritonavir (RTV) is a peptidomimetic HIV protease inhibitor with a chemical formula of 
C37H48N6O5S2 and a  molecular  weight  of  720.96  [The Merck Index].  It  is  a white  or 
almost white powder and may exhibit conformational polymorphism which necessitates 
special  precautions  in  the  manufacturing  process,  as  the  unwanted  RTV form II   is 
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therapeutically ineffective [Bauer et al. 2004]. The structural formula of RTV is depicted 
in Figure 4.
RTV was one of the first approved HIV protease inhibitors and is effective against both 
HIV-1 and HIV-2. However, it is also a strong inhibitor of CYP3A4 and weak inhibitor 
of CYP2D6. Special attention should therefore be paid to possible drug interactions with 
other substrates of these enzymes.
Major  side  effects  of  RTV  are  gastrointestinal  (GI)  and  include  nausea,  vomiting, 
diarrhea, anorexia, abdominal pain and taste perversion. In therapeutic doses of 600 mg 
twice  daily,  peripheral  and  perioral  paresthesias  can  occur.  RTV  can  also  cause  an 
increase in total serum cholesterol and triglycerides and probably the long-term risk for 
atherosclerosis.
Nowadays RTV is seldom used as sole protease inhibitor but mostly in combination with 
other agents of this class to boost their effectivity.  RTV inhibits the metabolism of all 
current HIV protease inhibitors and enhances their pharmacokinetic profile, allowing for 
a reduction dose and dosing frequency of coadministered drugs. The doses used to boost 
other HIV protease inhibitors are usually 100 or 200 mg once or twice daily, which is as 
effective  at  inhibiting CYP3A4 and much better  tolerated  than the 600 mg treatment 
[Goodman & Gilman's 2011].
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Figure 4: Structural formula of ritonavir
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1.3.2.2 Efavirenz
Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor with potent activity 
against HIV-1. Its chemical formula is C14H9ClF3NO2 and its molecular weight is 315.68. 
[The Merck Index].  The structural formula of EFV is depicted in Figure 5.
EFV  binds  HIV-1  RT  and  induces  a  conformational  change  that  greatly  reduces  its 
activity. It has no activity against host cell DNA polymerases.
Common adverse effects of EFV are central nervous symptoms like dizziness, insomnia 
and vivid dreams. Rash occurs frequently during the first few weeks of treatment. A rare 
but life-threatening side effect is Steven-Johnson syndrome. EFV is teratogenic [Calmy et
al. 2009].
The usual dose of EFV is 600 mg once daily.
1.3.2.3 Emtricitabine
Emtricitabine  (FTC)  is  a  nucleoside  reverse  transcriptase  inhibitor  with  a  structure 
derived from cytidine. The carbon atom in position 3´ of the ribose is substituted by a 
sulfur  atom,  thus  preventing  chain  elongation  in  reverse  transcription.  FTC  has  a 
chemical formula of C8H10FN3O3S and a molecular weight of 247.25 [The Merck Index]. 
The structural formula of FTC is depicted in Figure 6.
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Figure 5: Structural formula of  
efavirenz
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FTC itself  is  a  prodrug  and  exerts  its  antiretroviral  activity  only  after  activation  by 
cellular  kinases.  Its  active  metabolite,  emtricitabine  5´-triphosphate,  inhibits  HIV RT. 
FTC is effective against HIV-1, HIV-2 and HBV and has low affinity to human DNA 
polymerases,  explaining  its  low  toxicity  to  the  host  [Goodman  &  Gilman's  2011]. 
Significant adverse events are rare and include hyperpigmentation of the skin, especially 
in sun-exposed areas. Caution should be exercised in patients with hepatitis B infection, 
as severe exacerbations have been reported in patients who discontinued FTC [Calmy et
al. 2009].
FTC is usually used in doses of 200 mg once daily.
1.3.2.4 Tenofovir disoproxil fumarate
Tenofovir  is  a  nucleotide  reverse  transcriptase  inhibitor,  a  derivate  of  adenosine  5´-
monophosphate and the only nucleotide analogue currently marketed  for treatment  of 
HIV infection [Goodman & Gilman's 2011]. Unlike adenosine 5´-monophosphate it does 
not have a complete ribose ring, lacking the C3´. Its chemical formula is C9H14N5O4P and 
it has a molecular weight of 287.21. Tenofovir itself has very poor oral bioavailability, so 
a  disoproxil  prodrug is  used,  which significantly improves  oral  absorption as well  as 
cellular  penetration.  It  is  most  commonly used as fumarate  salt.  Tenofovir  disoproxil 
fumarate (TDF) occurs as white, fine powder-like crystals and has a chemical formula of 
C19H30N5O10P.C4H4O4  [The Merck Index]. The structural formula of TDF is depicted in 
Figure 7.
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Figure 6: Structural formula of emtricitabine
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The prodrug is  hydrolyzed  and tenofovir  is  phosphorylated  by cellular  kinases  to  its 
active  form,  tenofovir  diphosphate,  which  is  a  competitive  inhibitor  of  viral  RT and 
terminates elongation of nascent HIV DNA chains. Tenofovir is effective against HIV-1 
and HIV-2 as well as Hepatitis  B virus (HBV) and has low affinity to human DNA-
polymerases.
Tenofovir is generally well tolerated. However it should be used with caution in patients 
with preexisting renal diseases, as it is associated with small transient reductions of the 
estimated glomerular filtration rate and rare episodes of renal failure have been reported 
with tenofovir [Calmy et al. 2009].
TDF is  usually used in doses of 300 mg,  which corresponds to 245 mg of tenofovir 
disoproxil, once daily.
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Figure 7: Structural formula of tenofovir disoproxil fumarate
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1.4 Aim of study
The aim of the study is twofold. The first part  is to develop a monograph for RTV tablets 
for the Ph. Int. It should specify requirements for these tablets and provide methods of 
analysis for the verification of identity, dissolution testing, the detection of impurities and 
the quantification of the active ingredient.
Methods from the monograph of RTV drug substance in the Ph. Int. were checked for 
applicability to tablets, if necessary modified to meet the different requirements of this 
dosage  form  and  applied  to  commercial  samples  of  tablets.  Other  pharmaceutical 
compendia and scientific publications were consulted for additional information. 
In  accordance  with  the  aims  and  guidelines  of  the  Ph.  Int.,  simple  techniques  were 
employed where possible.
The second part deals with proposed monographs of two fixed dosage combinations that 
have  previously  been  developed  in  our  laboratory.  The  assay  methods  for  tablets 
containing FTC and TDF and for a combination of EFV, FTC and TDF were validated. 
ICH guidelines were used to identify the parameters of interest and establish a validation 
plan. Analyses were carried out to determine sensitivity,  linearity,  precision, including 
repeatability and intermediate precision, accuracy and range of the respective methods.
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2 Materials and Methods
2.1 Reagents and chemicals
Dichloromethane and sodium hydroxide pellets  were purchased from Fisher  scientific 
(Erembodegem,  Belgium).  HPLC-grade  acetonitrile  (ACN),  methanol  (MeOH)  and 
potassium permanganate  were purchased from VWR (Leuven,  Belgium).  Ammonium 
hydroxide  solution  and  decaethylene  glycol  monododecyl  ether  were  obtained  from 
Sigma-Aldrich (Seelze, Germany) and hydrochloric acid from J.T. Baker (Deventer, the 
Netherlands). Sodium dihydrogen phosphate dihydrate and sodium hexanesulfonate were 
purchased from Acros Organics (Geel, Belgium). Phosphoric acid and sulfuric acid were 
purchased from Chem Lab (Zedelgem, Belgium). Potassium dihydrogen phosphate was 
obtained from Merck (Darmstadt, Germany).
Demineralized  water  was purified  in  our  laboratory  by filtering  through an  ultrapure 
Milli-Q (Millipore, Milford, MA, USA). RTV, EFV, FTC and TDF drug substances, as 
well as RTV 100 mg tablets and EFV 600 mg/ FTC 200 mg/ TDF 300 mg tablets and 
FTC 200 mg/ TDF 300 mg tablets were donated by the WHO (Geneva, Switzerland).
2.2 Preparation of sample solutions
Sample  solutions  were  prepared  using  a  quantity  of  powdered  tablets  containing  the 
amount  of active ingredient  given in the corresponding method.  Therefore,  20 tablets 
were weighed and powdered. The average mass was calculated and used for determining 
the  required  amount  of  powdered  tablets,  which  was  then  dissolved  in  the  solvent, 
sonicated and filtered through a 0.45 µm membrane (Chromafil® RC-45/25, Macherey-
Nagel, Düren, Germany).
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2.3 Instrumentation and LC-conditions
2.3.1 Ritonavir tablets
Thin-layer chromatography (TLC) was performed using pre-coated TLC plates Silica gel 
60/  Kieselguhr  with  fluorescence  indicator  (F254)  (Merck,  Darmstadt,  Germany)  and 
Chromato-Vue  Model  CC-20  (Ultra-Violet  Products  Inc.,  Cambridge,  UK)  for 
examination in ultraviolet light (254 nm).
Ultraviolet  (UV) -  Spectra  were generated using a  Philips PU8740 UV/VIS scanning 
spectrophotometer.
A SR8 Plus Dissolution test station (Hanson Virtual Instruments, Chatsworth, USA) was 
used for dissolution testing.
Liquid  chromatography  (LC)  analyses  were  carried  out  on  a  LaChrome  Elite  LC 
apparatus  consisting  of  an  L-2130  Pump  (Merck-Hitachi),  an  L-2200  Autosampler 
(Merck-Hitachi),  an  L-2400  UV-Detector  (Merck-Hitachi)  and  an  Organizer  (Merck-
Hitachi).  EZChrom Elite  Version 3.1.6 (Scientific  Software Inc.,  Lincolnwood,  USA) 
was used for data acquisition. A Hypersil base deactivated silica (BDS) C18 column (250 
x 4.6 mm I.D.), 5 µm (Thermo Hypersil-Keystone, Cheshire, UK) was used as stationary 
phase. The column was immersed in a water bath and the temperature was kept at 35 °C 
by a Julabo EM heating immersion circulator (Seelbach, Germany). The flow rate was 
1.0 ml per minute and the UV-detector was set at 240 nm. The injection volume was 20 
µl.
pH measurements were performed with a Metrohm 691 pH-Meter (Metrohm, Antwerp, 
Belgium).
2.3.2 Efavirenz, emtricitabine and tenofovir disoproxil fumarate 
tablets
Liquid chromatography (LC) analyses were carried out on two different LC apparatus. 
The first one was a LaChrome apparatus, consisting of an L-7100 Pump (Merck-Hitachi), 
an L-7200 Autosampler (Merck-Hitachi), an L-7400 UV-Detector (Merck-Hitachi), a D-
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7000  Interface  (Merck-Hitachi)  and  an  L-7614  Degasser  (Merck).  EZChrom  Elite 
Version  3.1.6  (Scientific  Software  Inc.,  Lincolnwood,  USA)  was  used  for  data 
acquisition.  LC-apparatus  II  was  an  UltiMate  3000-system,  comprising  Pump, 
Autosampler and Diode Array Detector, using Chromeleon 6.80 for data acquisition. A 
Hypersil  BDS C18 column (250 x 4.6 mm I.D.),  5  µm (Thermo Hypersil-Keystone, 
Cheshire, UK) was used as stationary phase. Also Brava BDS (250 x 4.6 mm I.D.), 5 µm 
(Alltech,  Deerfield,  Illinois,  USA  ),  HyPurity  Elite  C18 (150 x 4.6 mm I.D.),  3  µm, 
HyPurity C18 (250 x 4.6 mm I.D.), 5 µm, HyPurity Elite C18 (150 x 4.6 mm I.D.), 5 µm 
(ThermoQuest, Cheshire, UK) and Discovery C18 (250 x 4.6 mm I.D.), 5 µm (Supelco, 
Bellefonte, PA, USA) columns were tested. The columns were immersed in water baths 
and the  temperature was kept  at  35 °C by Julabo EM heating  immersion  circulators 
(Seelbach, Germany). The flow rate was 1.0 ml per minute, the UV-detectors were set at 
280 nm. The injection volume was 20 µl.
2.4 Mobile phases
2.4.1 Ritonavir tablets
Gradient elution was employed, using two mobile phases with different concentrations of 
ACN, phosphate buffer pH 4.0 and water. Mobile phase A consisted of 35 volumes of 
ACN, 28 volumes of phosphate buffer pH 4.0 and 37 volumes of water. Mobile Phase B 
contained 70 volumes of ACN, 28 volumes of phosphate buffer pH 4.0  and 2 volumes of 
water.
The phosphate buffer was prepared by dissolving 7.8 g of sodium dihydrogen phosphate 
dihydrate and 1.88 g of sodium hexanesulfonate in 800 ml of purified water, adjusting the 
pH to  4.0 by adding phosphoric  acid  (~ 105 g/l)  and then  diluting  to  1000 ml  with 
purified water.  Phosphoric acid (~ 105 g/l) was prepared by diluting 115 g of phosphoric 
acid 85% with purified water to make 1000 ml solution.
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Table 2: Gradient programme for LC analysis of ritonavir tablets
Time
(min)
Mobile phase A
(% v/v)
Mobile Phase B
(% v/v)
Comments
0-20 70 30 Isocratic
20-30 70 to 0 30 to 100 Linear gradient
30-40 0 100 Isocratic
40-45 0 to 70 100 to 30 Return to initial composition
45-50 70 30 Re-equilibration
2.4.2 Efavirenz, emtricitabine and tenofovir disoproxil fumarate 
tablets
A gradient programme, as given in the monograph was used. Mobile phase A consisted 
of 5 volumes of phosphate solution and 95 volumes of water. Mobile Phase B contained 
70 volumes of ACN, 5 volumes of phosphate solution and 25 volumes of water. The 
phosphate  solution  was  prepared  by  dissolving  27.22  g  of  potassium  dihydrogen 
phosphate in 1000 ml of purified water. 
Table 3: Gradient programme for LC analysis of EFV/FTC/TDF tablets
Time
(min)
Mobile phase A
(% v/v)
Mobile Phase B
(% v/v)
Comments
0-9 93 7 Isocratic
9-15 93 to 0 7 to 100 Linear gradient
15-19 0 100 Isocratic
19-19.1 0 to 93 100 to 7 Return to initial composition
19.1-30 93 7 Re-equilibration
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3 Results and discussion
3.1 Development of a monograph for ritonavir tablets
The monograph for RTV drug substance in the Ph. Int. was used as a starting point for 
developing a monograph for RTV tablets [The International Pharmacopoeia, 4th edition]. 
General  information  was  gathered  according  to  guidelines  for  the  development  of 
monographs  for  the  Ph.  Int.  by  consulting  the  corresponding  parts  of  the  Indian 
Pharmacopoeia  (IP)  [Indian  Pharmacopoeia,  5th  edition],  European  Pharmacopoeia 
[European Pharmacopoeia, 7th edition] and the WHO list of essential medicines[WHO
Model List  of Essential  Medicines].  Specific  tests  for identity,  impurities and content 
were taken from the drug substance monograph in the Ph. Int. and, as far as they were 
applicable to tablets, applied to the sample. It was found necessary for some of these tests 
to make minor adjustments in order to use them for the analysis of RTV tablets, whereas 
others were found to be not suitable for this dosage form.
To  fulfill  the  requirement  of  a  dissolution  test,  the  method  from  the  RTV  tablet 
monograph in the IP  [Indian Pharmacopoeia, 5th edition] and a method taken from the 
FDA-Database [FDA-dissolution database] for dissolution tests were adapted and applied 
to the sample, the former of which was included in the proposed monograph for reasons 
of availability of chemicals used for medium preparation and easier handling.
3.1.1 The Proposed Monograph
The monograph as proposed for inclusion in the Ph. Int.:
Ritonaviri Compressi
Ritonavir Tablets
Category. Antiretroviral (Protease Inhibitor).
Storage. Ritonavir tablets should be stored at temperatures not exceeding 30 °C.
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Additional information. Strength in the current WHO Model list of essential medicines: 
25 mg, 100 mg of ritonavir.
Requirements
Comply with the monograph for “Tablets”.
Definition.  Ritonavir tablets contain not less than 90.0% and not more than 110.0% of 
the amount of ritonavir (C37H48N6O5S2) stated on the label.
Identity tests
A. Carry out test A.1 or, where UV detection is not available, test A.2.
A.1 Carry out the test as described under 1.14.1 Thin-layer chromatography,
using silica gel R6 as the coating substance and a mixture of 67 volumes 
of  dichloromethane  R,  20  volumes  of  acetonitrile  R,  10  volumes  of 
methanol R and 3 volumes of ammonia (~260 g/l) TS as the mobile phase. 
Apply separately to the plate 10 µl of each of the following solutions. For 
solution (A) shake a quantity of the powdered tablets equivalent to 25 mg 
of ritonavir with 5 ml methanol and filter. Add 0.5 ml of ammonia (~260 
g/l)  to  2.0  ml  of  the  filtrate  and shake.  For  solution  (B) use  5 mg of 
ritonavir RS per ml, add 0.5 ml of ammonia (~260 g/l) to 2.0 ml of the 
solution and shake. After removing the plate from the chromatographic 
chamber, allow it to dry exhaustively in a current of cool air. Examine the 
chromatogram in ultraviolet light (254 nm).
The  principal  spot  obtained  with  solution  A  corresponds  in  position, 
appearance and intensity with that obtained with solution B.
A.2 Carry out the test as described under 1.14.1 Thin-layer chromatography, 
using the conditions described above under test A.1 but using silica gel R5 
as the coating substance. Spray lightly with basic potassium permanganate 
(5 g/l) TS and examine the chromatogram in daylight.
The  principal  spot  obtained  with  solution  A  corresponds  in  position, 
appearance, and intensity with that obtained with solution B.
B. See the test described under Assay. The retention time of the principal peak in the 
chromatogram  obtained  with  the  test  solution  is  similar  to  that  in  the 
chromatogram obtained with the reference solution.
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Dissolution.  Carry out  the test  as  described under  5.5 Dissolution  test  for  solid  oral 
dosage forms, using as the dissolution medium, 900 ml of hydrochloric acid (0.1 mol/l) 
VS, and rotating the paddle at 100 revolutions per minute.  At 60 minutes withdraw a 
sample of 10 ml of the medium through an in-line filter. Allow the filtered sample to cool 
down to room temperature.
Determine  the  content  of  ritonavir  (C37H48N6O5S2)  in  the  medium  by  1.14.4  High-
performance liquid chromatography, using the conditions described under Assay using a 
suitable ritonavir RS solution as a reference solution.
For each of the six tablets tested, calculate the total amount of ritonavir (C37H48N6O5S2) in 
the medium from the results obtained. The amount in solution for each tablet is not less 
than 80% of the amount stated on the label. If the amount obtained for one of the six 
tablets is less than 80%, repeat the test using a further six tablets; the average amount for 
all 12 tablets tested is not less than 75% and the amount obtained for no tablet is less than 
60%.
Related substances
Carry out the test as described under 1.14.4 High-performance liquid chromatography, 
using the conditions described under Assay.
Prepare the following solutions using a mixture of 70 volumes of mobile phase A and 30 
volumes of mobile phase B as diluent. For solution (1) shake a quantity of powdered 
tablets containing 25 mg of ritonavir with 50 ml of the diluent, filter and use the clear 
filtrate. For solution (2) dilute a suitable volume of solution (1) to obtain a concentration 
of 0.5 µg of ritonavir per ml.
For the system suitability test: prepare solution (3) using 5 ml of solution (1) and 1 ml of 
sulfuric acid (475 g/l), heat in a boiling water bath for 20 minutes.
Operate  with  a  flow  rate  of  1.0  ml  per  minute.  As  a  detector  use  an  ultraviolet  
spectrophotometer set at a wavelength of 240 nm.
Maintain the column temperature at 35 °C.
Inject  20  µl  of  solution  (3).  The  test  is  not  valid  unless  the  resolution  between  the 
principal peak (retention time about 22 minutes) and the peak with a relative retention of 
about 0.8 is not less than 2.0. The test is also not valid unless the resolution between the 
principal peak and the peak with a relative retention of about 1.5 is not less than 6.5. If 
necessary adjust the amount of acetonitrile in both mobile phases A and B, or adjust the 
gradient program.
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Inject alternatively 20 µl each of solutions (1) and (2).
In the chromatogram obtained with solution (1), the area of any peak, other than the 
principal peak, is not greater than three times the area of the principal peak obtained with 
solution (2) (0.3%). In the chromatogram obtained with solution (1), the areas of not 
more than two peaks, other than the principal peak, are greater than twice the area of the 
principal peak obtained with solution (2) (0.2%) and the areas of not more than four such 
peaks are greater than the area of the principal peak obtained with solution (2) (0.1%). 
The sum of the areas of all peaks, other than the principal peak, is not greater than ten 
times the area of the principal peak obtained with solution (2) (1%). Disregard any peak 
with  an area  less  than 0.5 times  the  area of  the  principal  peak in  the  chromatogram 
obtained with solution (2) (0.05%). Disregard any peak with a retention time less than the 
retention time of the peak obtained in the system suitability test with a relative retention 
of about 0.5.
Assay
Carry out the test as described under 1.14.4 High-performance liquid chromatography, 
using a stainless steel column (25 cm x 4.6 mm) packed with base-deactivated particles 
of  silica  gel  the  surface  of  which  has  been  modified  with  chemically  bonded 
octadecylsilyl groups (5 µm)1.
Use the following conditions for gradient elution:
Mobile phase A: 35 volumes of acetonitrile R, 28 volumes sodium phosphate buffer 
    pH 4.0 and 37 volumes of purified water.
Mobile phase B: 70 volumes of acetonitrile R, 28 volumes sodium phosphate buffer
    pH 4.0 and 2 volumes of purified water.
Prepare the sodium phosphate buffer pH 4.0 by dissolving 7.8 g of sodium dihydrogen 
phosphate dihydrate R and 1.88 g of sodium hexanesulfonate R in 800 ml of purified 
water, adjust the pH to 4.0 by adding phosphoric acid (~105 g/l) TS and dilute to 1000 ml 
with purified water.
1  Hypersil BDS C18 has been found suitable 
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Time
(min)
Mobile phase A
(% v/v)
Mobile Phase B
(% v/v)
Comments
0-20 70 30 Isocratic
20-30 70 to 0 30 to 100 Linear gradient
30-40 0 100 Isocratic
40-45 0 to 70 100 to 30 Return to initial 
composition
45-50 70 30 Re-equilibration
Prepare the following solutions using a mixture of 70 volumes of mobile phase A and 30 
volumes of mobile phase B as diluent. For solution (1) shake a quantity of powdered 
tablets containing 25 mg of ritonavir with 50 ml of the diluent, filter and use the clear 
filtrate. For solution (2) use 0.5 mg of ritonavir RS per ml of the diluent.
Operate  with  a  flow  rate  of  1.0  ml  per  minute.  As  a  detector  use  an  ultraviolet  
spectrophotometer set at a wavelength of 240 nm.
Maintain the column temperature at 35 °C.
For the system suitability test: prepare solution (3) using 5 ml of solution (1) and 1 ml of 
sulfuric acid (475 g/l), heat in a boiling water bath for 20 minutes.
Inject  20  µl  of  solution  (3).  The  test  is  not  valid  unless  the  resolution  between  the 
principal peak (retention time about 22 minutes) and the peak with a relative retention of 
about 0.8 is not less than 2.0. The test is also not valid unless the resolution between the 
principal peak and the peak with a relative retention of about 1.5 is not less than 6.5.
Inject alternatively 20 µl each of solutions (1) and (2).
Measure the areas of the peak responses obtained in the chromatograms from solutions 
(1) and (2), and calculate the content of ritonavir (C37H48N6O5S2) in the tablets.
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3.1.2 Development of the monograph
3.1.2.1 Requirements
The general monograph for tablets in the Ph. Int. provides definitions, information and 
requirements regarding manufacture, labeling and storage as well as some tests, such as 
visual  inspection,  uniformity  of  mass,  uniformity  of  content  and  a  dissolution  test. 
Specific information not given in the general monograph was included in the proposed 
monograph.
20 random tablets  were subjected  to  visual  inspection  to  see if  they are undamaged, 
smooth  and  of  uniform  color.  The  same  tablets  were  weighed  singly  to  perform  a 
uniformity of mass test. The average mass and the deviation of the mass of each tablet 
from the average mass were calculated. The mass of a minimum of 18 tablets must not 
deviate more than 5% from the average mass, and the mass of not more than two tablets 
may deviate by more than 10% from the average mass.
The tablets examined complied with these specifications. Detailed results are given in the 
annex.
3.1.2.2 Definition
The requirements given under definition were established in accordance with the limits 
generally used for dosage forms.
3.1.2.3 Identity tests
The  Ph.  Int.  monograph  for  RTV drug  substance  does  give  four  Identity  tests  [The
International  Pharmacopoeia,  4th  edition].  Two  of  them  employ  TLC,  one  UV-
Spectrophotometry and one infrared (IR) - Spectroscopy.
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3.1.2.3.1 Thin-Layer chromatographic methods
Identity Test A.1 was applied to the sample using pre-coated TLC plates Silica gel 60/ 
Kieselguhr F254 and a mixture of 67 volumes of dichloromethane, 20 volumes of ACN, 10 
volumes of methanol and 3 volumes of ammonium hydroxide solution 25% as the mobile 
phase.  The  sample  solution  was  prepared  by shaking a  quantity  of  powdered  tablets 
equivalent  to  25  mg  of  RTV  with  5  ml  of  methanol  and  filtering  it.  A  RTV  drug 
substance solution of 5 mg/ml in methanol was used as reference solution. 10 µl of each 
solution  were  applied  to  the  plate  using  a  Hamilton  syringe.  After  developing  the 
chromatograms, the plates were allowed to dry and examined under ultraviolet light (254 
nm).
Identity  test  A.2  was  carried  out  using  the  conditions  described  under  test  A.1  and 
examined in daylight after spraying with basic potassium permanganate solution (5 g/l). 
The basic potassium permanganate solution was prepared by dissolving 4 g of sodium 
hydroxide in 100 ml of purified water and adding 0.5 g of potassium permanganate.
The  principal  spot  obtained  with  the  sample  solution  should  correspond  to  the  spot 
obtained with the reference solution in position, appearance and intensity. However, the 
chromatogram exhibited strong tailing for the sample (Figure 8).
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Figure 8: TLC-chromatograms obtained  from Identity Test  
A.1. (left) and A.2. (right) with the method from the  
monograph of ritonavir drug substance
pH-values of both solutions were measured to see if there is any difference but were 
found to be 5 for both solutions.
It was decided to add ammonium hydroxide solution 25% to the sample solution, under 
the assumption that the tablets contain RTV in its protonated form and this being the 
reason for the strong tailing.
The tailing was significantly reduced by adding ammonia, whereupon different amounts 
of ammonia were tried, and a quantity of 0.5 ml ammonia per 2 ml of sample solution 
was found to be reasonable. To achieve the same degree of dilution for both the sample 
and the reference solution, the addition of ammonia to both solutions was included in the 
proposed monograph (Figure 9).
3.1.2.3.2 Spectrophotometric methods
UV-Spectrophotometry
Two reference solutions were prepared by dissolving 20 mg of RTV drug substance in 
100 ml of methanol each and further diluting 5 ml of each solution to 25 ml with the 
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Figure 9: TLC-chromatograms obtained from Identity Test  
A.1. (left) and A.2. (right) with the method from the  
proposed monograph
same solvent. Spectra were recorded in triplicate for each solution. A typical reference 
spectrum is shown in Figure 10.
Two sample solutions with a concentration of 40 µg/ml RTV in methanol were prepared 
by dissolving a quantity of powdered tablets equivalent to 20 mg of RTV in methanol and 
then diluting 5 ml of the obtained solution to 25 ml with methanol. Spectra in the range of 
220 to 280 nm were recorded in triplicate for both solutions. According to the RTV drug 
substance  monograph,  the  spectrum  exhibits  a  maximum  at  240  nm.  The  spectrum 
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Figure 10: UV-spectrum obtained with reference solution
obtained with the sample solution does, however, not display this maximum (Figure 11). 
This is probably due to the influence of excipients contained in the dosage form.
Unlike the spectrum obtained with the sample solution, the reference spectrum clearly 
exhibits a maximum at 240 nm, as described in the monograph for RTV drug substance. 
It was concluded that the UV-Spectrophotometric method described in the drug substance 
monograph is not appropriate for identification of RTV tablets and therefore not included 
in the proposed monograph.
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Figure 11: UV-spectrum obtained with sample solution
IR-Spectroscopy
The IR-spectroscopic method provided by the RTV drug substance monograph was not 
applied to the tablets, as it is well established that due to the influence of excipients the 
spectrum obtained with this dosage form does clearly differ from a spectrum obtained 
with the drug substance or a reference spectrum.
LC
To  provide  an  alternative  to  the  TLC-tests,  it  was  proposed  to  use  the  LC-method 
described under Assay for identification of RTV tablets by comparing the retention times 
of  the  principal  peaks  obtained  with  the  sample  solution  and  reference  solution.  A 
corresponding suggestion is included in the proposed monograph as Identity test B. An 
overlay of chromatograms of sample solution and reference solution obtained with the 
assay method is shown in Figure 12.
3.1.2.4 Dissolution test
Two different methods for dissolution tests were applied to the sample. The first one was 
taken from the IP monograph for RTV tablets  [Indian Pharmacopoeia, 5th edition]. It 
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Figure 12: Overlay of chromatograms of sample solution (black) and reference solution (blue) obtained  
with the assay method
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Ritonavir 
uses the “paddle”-apparatus, with 900 ml of hydrochloric acid (0.1 mol/l) as dissolution 
medium and the paddle rotating at 100 revolutions per minute. The dissolution medium 
was prepared by diluting 9.85 g of hydrochloric acid 37% to 1000 ml with purified water. 
After  60  minutes,  samples  were  drawn,  filtered,  allowed  to  cool  down  to  room 
temperature and analyzed by LC, using the method described under assay in the Ph. Int. 
drug  substance  monograph.  A  0.1  mg/ml  RTV  drug  substance  solution,  which  was 
prepared by dissolving 20 mg of RTV drug substance in 20 ml of methanol and diluting 5 
ml of this solution to 50 ml with the dissolution medium, was used as reference solution. 
The  amount  of  RTV  in  the  dissolution  medium  was  calculated  using  the  following 
equation:
X= a * 90 / b
with X: amount of RTV in the dissolution medium (mg/ml)
a: response of the sample solution (normalized area)
b: response of the reference solution (normalized area)
The acceptance criterion given in the IP is not less than 80% for each tablet. The Ph. Int.  
does  provide  general  acceptance  criteria  for  dissolution  tests  in  the  “Methods  of 
Analysis”  part,  which  consist  of  three  stages  [The  International  Pharmacopoeia,  4th
edition].
The average total amount of RTV in the dissolution medium for six tablets was 85.16 mg, 
which corresponds to 85.16% of the amount stated on the label. However, the amount for 
one tablet was below 80% and by using the limit from the IP, which was found to be 
reasonable, and by applying the criteria from the Ph. Int., another 6 tablets were analyzed 
to see whether the sample complies with the second stage. To meet these criteria, the 
average of 12 tablets has to be equal to or greater than 75%, and the amount of no tablet  
must be less than 60%. The average of all 12 tablets was 83.64% and the amount of no 
tablet was below 60%. Thus the sample complied with the second stage.
The second method was taken from the FDA-database for dissolution methods  [FDA-
dissolution database]. It also employs the “paddle”-apparatus but uses 900 ml of 60 mM 
Polyoxyethylene 10 laurylether  as dissolution medium and 75 revolutions per minute.  
Samples  were  drawn  after  60  minutes,  filtered  and  allowed  to  cool  down  to  room 
temperature. Quantification was done by LC, using the same method as described above. 
The average total amount of RTV in the dissolution medium for six tablets was 84.29 
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mg/ml,  which corresponds to 84.29%. When applying the same criteria as in the first 
method, two tablets failed, so another six tablets were analyzed. The average of all 12 
tablets was 90.05% and the amount of no tablet was below 60%.
Due to easier availability of chemicals for medium preparation and easier handling, the 
first  method  was  preferred  for  inclusion  in  the  proposed  monograph.  The  limit  for 
acceptance given in the IP was found to be reasonable and, combined with the general 
criteria from the Ph. Int., included as specific information in the proposed monograph.
3.1.2.5 Related substances
The method given in the Ph. Int. monograph for RTV drug substance was applied to the 
sample [The International Pharmacopoeia, 4th edition]. Sample solution (1) was prepared 
by shaking a quantity of powdered tablets containing 25 mg of RTV with 50 ml of mobile 
phase A, sonicating and filtering, to obtain a concentration of 0.5 mg RTV per ml.
When preparing the sample solutions, a solubility problem was encountered, which also 
occurred  when  preparing  solutions  with  RTV  drug  substance.  In  spite  of  excessive 
sonication, the samples did not dissolve properly. Therefore, the dissolution medium was 
changed to a mixture of 70 volumes of mobile phase A and 30 volumes of mobile phase 
B, which corresponds to the initial composition of the mobile phase in the LC-method. 
The  modified  preparation  of  solutions  was  included  in  the  proposed  monograph 
accordingly.
To perform the  system suitability  test,  solution  (3)  was prepared  by adding 1  ml  of 
sulfuric acid (~ 475 g/l) to 5 ml of solution (1) and heating in a boiling water bath for 20 
minutes. The sulfuric acid was prepared by diluting 4.95 g of sulfuric acid 96% to 10 ml 
with  water.  This  solution  was  then  analyzed  with  the  given  LC-method.  A  typical 
chromatogram  of  RTV  tablets  solution  obtained  under  the  system  suitability  test 
conditions is shown in figure 13.
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According to the Ph. Int. monograph for RTV drug substance, the test is not valid unless 
the resolution between the principal peak and the peak with a relative retention of about 
0.8 is not less than 3.5 and unless the resolution between the principal peak and the peak 
with a relative retention of about 1.5 is higher than 9.0 [The International Pharmacopoeia,
4th edition].
It  was,  however,  not  possible  to  meet  these  requirements,  in  spite  of  repeating  the 
degradation and analyzing the degraded solution several times and using other columns 
of the same type. Finally system suitability criteria were adapted in accordance with the 
results obtained and with respect to reasonable limits for resolution.
Next, solution (2) was prepared by diluting solution (1) with a mixture of mobile phases 
A/B 70:30 (v/v), to obtain a concentration of 0.5 µg RTV per ml, which corresponds to 
0.1% RTV. Both solutions were prepared in duplicate and analyzed with LC in triplicate 
(Figures 14 and 15).
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Figure  13:  A  typical  chromatogram of  ritonavir  tablets  solution  obtained  under  the  system suitability  test  
conditions
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Figure 14: A typical chromatogram obtained with solution (1), 0.5 mg/ml RTV
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Figure 15: A typical chromatogram obtained with solution (2), 0.5 μg/ml RTV
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The  content  of  each  impurity  found  with  solution  (1)  was  then  calculated  using  the 
response  obtained  with  solution  (2)  as  a  reference  of  0.1%.  The  results  were  then 
compared to the criteria in the RTV monograph in the Ph. Int.:
“In the chromatogram obtained with solution (1), the area of any peak, other than the 
principal peak, is not greater than three times the area of the principal peak obtained with 
solution (2) (0.3%). In the chromatogram obtained with solution (1), the areas of not 
more than two peaks, other than the principal peak, are greater than twice the area of the 
principal peak obtained with solution (2) (0.2%) and the areas of not more than four such 
peaks are greater than the area of the principal peak obtained with solution (2) (0.1%). 
The sum of the areas of all peaks, other than the principal peak, is not greater than ten 
times the area of the principal peak obtained with solution (2) (1.0%). Disregard any peak 
with  an area  less  than 0.5 times  the  area of  the  principal  peak in  the  chromatogram 
obtained with solution (2) (0.05%).”[The International Pharmacopoeia, 4th edition]
It was furthermore decided to disregard peaks with a retention time less than the retention 
time of the peak obtained in the system suitability test (SST) with a relative retention of 
about  0.5,  as a lot  of peaks in that  area are probably due to  excipients  and not  well 
separated. A typical chromatogram obtained under the SST conditions with relevant SST 
peaks is shown in Figure 16.
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In the sample analyzed, one impurity above the disregard limit was found (Figure 14), 
with a content  of 0.08%. Thus, applying the criteria  of the proposed monograph,  the 
sample complies.
3.1.2.6 Assay
The RTV drug substance monograph in the Ph. Int. does prescribe a titration method 
using perchloric acid to determine the content of RTV in the sample  [The International
Pharmacopoeia,  4th edition].  However,  due to the influence of excipients  the method 
used for the drug substance is not applicable to the tablets.
The  LC  method  was  applied  for  quantification,  using  a  sample  solution  with  a 
concentration of 0.5 mg RTV per ml in a mixture of mobile phases A/B 70:30 (v/v). An 
RTV drug substance solution of the same concentration in the same solvent was used as 
reference. Solutions were prepared in duplicate and analyzed in triplicate. An overlay of 
typical chromatograms of sample solution and reference solution is shown in Figure 12.
39
Figure 16: A typical chromatogram of ritonavir tablets solution obtained under the system suitability test (SST)  
conditions with numbered SST peaks
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The  average  content  of  RTV  in  the  sample  tablets  was  then  calculated  using  the 
normalized area values of all four solutions. The sample complies with the limits given in 
the proposed monograph, the content of RTV in the sample was found to be 101.3%.
Using the  UV-Spectroscopic  method  given in  the  Ph.  Int.  monograph  for  RTV drug 
substance  under  Identity  test  as  an  alternative  was  also  considered,  but,  as  has  been 
described under Identity test, this turned out to be not feasible, as the difference between 
the spectrum obtained with the sample solution of the drug product and the reference 
spectrum is too big. Furthermore calculations were done to determine the content of RTV 
in the sample. The equation
a = A/(b*c)
with a: absorptivity
A: absorbance
b: absorption path length (in cm)
c: concentration of the substance (in g/l)
was  used  to  calculate  the  concentrations  of  both  sample  and reference  solution.  The 
content calculated this way was found to be higher than can reasonably be expected and 
clearly  different  from  the  results  obtained  with  the  LC  method.  Therefore  no  UV-
spectroscopic method for quantification was included in the proposed monograph.
3.2 Validation of assay methods
The second part of the project was to validate assay methods of monographs that had 
previously been developed in our laboratory and proposed for inclusion in the Ph. Int. 
The first monograph is for tablets containing a combination of EFV/FTC/TDF and the 
second one for tablets containing FTC/TDF. 
The LC method used had been developed for the related substances test of FTC drug 
substance and was then applied to different dosage forms and fixed-dose combinations of 
this drug, amongst others the aforementioned. It had been selected because it offers good 
separation at a reasonable runtime. It was used for determining the content of FTC/TDF 
tablets and in a modified way also for the assay of EFV/FTC/TDF tablets.
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The  International  Conference  on  Harmonisation  of  Technical  Requirements  for 
Registration  of  Pharmaceuticals  for  Human  Use  (ICH)  guidelines  for  validation  of 
analytical  procedures  were  consulted  and a  plan  for  the  validation  was  drafted  [ICH
guidelines 2005]. It was decided to carry out tests to determine the following parameters:
• Sensitivity
• Linearity
• Precision
 Repeatability
 Intermediate Precision
• Accuracy
• Range
3.2.1 EFV/FTC/TDF tablets
The assay method extracted from the Ph. Int. monograph is given as follows:
Assay
Carry out the test as described under  1.14.4 High-performance liquid chromatography, 
using a stainless steel column (25 cm x 4.6 mm) packed with base-deactivated particles 
of  silica  gel  the  surface  of  which  has  been  modified  with  chemically  bonded 
octadecylsilyl groups (5 μm).
The mobile  phases  for  gradient  elution  consist  of  a  mixture  of  Mobile  phase A and 
Mobile phase B, using the following conditions:
Mobile phase A: 5 volumes of phosphate solution and 95 volumes of water R.
Mobile phase B: 70 volumes of acetonitrile R, 5 volumes of phosphate solution and 
25 volumes of water R.
Prepare the phosphate solution by dissolving 27.22 g of potassium dihydrogen phosphate 
R in 1000 ml of water R.
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Table 4: Gradient programme for LC analysis of  EFV/FTC/TDF tablets
Time
(min)
Mobile phase A
(% v/v)
Mobile phase B
(% v/v)
Comments
0 – 9 93 7 Isocratic
9 – 15 93 to 0 7 to 100 Linear gradient
15 – 19 0 100 Isocratic
19 – 19.1 0 to 93 100 to 7 Return to initial 
composition
19.1-30 93 7 Re-equilibration
After preparation, keep the solutions at about 6 °C, or use an injector with cooling.
Prepare the following solutions using a mixture of 20 volumes of acetonitrile  and 80 
volumes of water R as a diluent. For solution (1) weigh and powder 20 tablets. Disperse a 
quantity  of  the  powder  containing  about  10  mg  of  tenofovir  disoproxil  fumarate, 
accurately weighed in 100 ml of the diluent and filter. For solution (2) dissolve quantities 
of efavirenz RS, tenofovir disoproxil fumarate RS and emtricitabine RS in the diluent to 
obtain a concentration of 0.2 mg/ml, 0.1 mg/ml and 66.7 µg/ml of efavirenz, tenofovir 
disoproxil  fumarate  and  emtricitabine,  respectively.  For  solution  (c) use  0.02  mg  of 
fumaric acid R per ml of water R.
If needed, adapt the concentration of solution (2) in function of the tablet composition.
Operate  with  a  flow  rate  of  1.0  ml  per  minute.  As  a  detector  use  an  ultraviolet  
spectrophotometer set at a wavelength of 280 nm.
Maintain the column temperature at 35°C.
Inject alternatively 20 µl each of solutions (1), (2) and (3).
The test is not valid unless in the chromatograms obtained with solutions (1) and (2), four 
principal  peaks  with the indicated retention times are shown: fumarate (about 2.5 
minutes), emtricitabine (about 9 minutes), tenofovir disoproxil (about 18 minutes) 
and efavirenz (about 22 minutes).
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Calculate  the contents  of  efavirenz  (C14H9ClF3NO2),  emtricitabine  (C8H10FN3O3S) and 
tenofovir  disoproxil  fumarate  (C19H30N5O10P,C4H4O4)  in  the  tablets  from the  declared 
contents of efavirenz RS, emtricitabine RS and tenofovir disoproxil fumarate RS.
3.2.1.1 Sensitivity
The sensitivity of the method was determined with respect to the limit of detection (LOD) 
and the limit of quantification (LOQ). LOQ for EFV, FTC and TDF were 0.49%, 0.06% 
and  0.50% and  LOD 0.15%,  0.02% and  0.15%,  respectively.  The  percentages  were 
calculated with respect to the main component nominal value (200 µg/ml = 100% for 
EFV, 66.7 µg/ml = 100% for FTC and 100 µg/ml = 100% for TDF, 20 µl injected).
3.2.1.2 Linearity
Linearity was established from 0.5 to 125% of the test concentration, using 5 different 
concentrations.  A  solution  of  EFV,  FTC and  TDF  in  MeOH:H2O,  50:50  (v/v)  with 
concentrations corresponding to 250% of the test concentration was prepared and then 
mixed 50:50 with the solvent to obtain a 125% solution. This was in turn diluted with the 
solvent  to  obtain  solutions  with  concentrations  of  100,  50,  5  and  0.5%  of  the  test 
concentration  (100 % = 0.2mg/ml  EFV,  66.7 µg/ml  FTC and  0.1 mg/ml  TDF).  The 
solutions  were  analyzed  in  triplicate,  the  average  response  for  each  solution  was 
calculated and used to create a plot depicting the response as a function of concentration 
(Figure 17).
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Table 5: Findings for linearity of the assay method for EFV/FTC/TDF tablets
EFV FTC TDF
Concentration 
(µg/ml)
1-250 0.33-83.3 0.5-125
Coefficient of 
determination (R²)
1 1 0.9996
Regression equation y = 28847x + 269.89 y = 86762x - 5669.2 y = 21367x + 15125
As can be seen from Figure 17 and Table 5, the method is linear in the investigated range.
3.2.1.3 Precision
Precision was determined by assessing repeatability and intermediate precision.
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Figure 17: Linearity of the assay method for EFV/FTC/TDF tablets
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3.2.1.3.1 Repeatability
Repeatability was assessed using six determinations at 100% of the test concentration. 
Therefore, a reference solution containing EFV, FTC and TDF at 100% of the nominal 
test concentration was prepared and injected six times, as well as a sample solution. The 
sample solution was prepared by dissolving EFV, FTC and TDF in MeOH:H2O, 50:50 
(v/v), to obtain concentrations of 0.2 mg EFV, 66.7 µg FTC and 0.1 mg TDF per ml. 
After normalizing the response areas, the average content of EFV, FTC and TDF in the 
sample  was calculated,  and standard  deviation  and relative  standard  deviation  (RSD) 
were determined. The results are given in Table 6.
Table 6: Findings for repeatability of the assay method for EFV/FTC/TDF tablets
EFV FTC TDF
Average content 102.1% 97.5% 96.2%
Standard deviation 0.5 0.4 0.3
%RSD 0.5 0.4 0.3
As can be seen from Table 6, the RSD values for each component were not more than 
0.5%, indicating that the method is repeatable.
3.2.1.3.2 Intermediate Precision
Intermediate  precision  was  established  by  injecting  a  reference  solution  of  drug 
substances at a concentration of 100% of the nominal test concentration and the sample 
solution six times each, over four days. The analyses of days 1 and 2 were carried out on 
LC-apparatus I, those of days 3 and 4 on LC-apparatus II and with a different column. 
After normalization, the average content of EFV, FTC and TDF, standard deviation and 
RSD were calculated for each day (Table 7). RSD was also determined for days 1+2, 3+4 
and all four days (Table 8). 
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Table 7: Findings for intermediate precision of the assay method for EFV/FTC/TDF tablets
Day 1 Day 2
EFV FTC TDF EFV FTC TDF
Average 
content
102.1% 97.5% 96.2% 104.8% 97.5% 96.1%
Standard 
deviation
0.5 0.4 0.3 0.8 0.6 0.5
%RSD 0.5 0.4 0.3 0.8 0.6 0.5
Day 3 Day 4
EFV FTC TDF EFV FTC TDF
Average 
content
104.2% 97.4% 96.5% 105.4% 98.4% 96.9%
Standard 
deviation
0.05 0.4 0.06 0.2 0.5 0.1
%RSD 0.05 0.4 0.06 0.2 0.5 0.1
Table 8: Summarized findings for intermediate precision of the assay method for EFV/FTC/TDF tablets
Days 1+2 Days 3+4 All 4 days
EFV FTC TDF EFV FTC TDF EFV FTC TDF
%RSD 0.6 0.5 0.4 0.1 0.4 0.09 0.4 0.5 0.2
As can be seen from Tables 7 and 8, the RSD values for each component were not more 
than 0.5%, indicating that the method is precise.
3.2.1.4 Accuracy
According  to  the  ICH  guidelines,  several  methods  are  available  for  determining  the 
accuracy of a method for the assay for drug products [ICH guidelines 2005]. As not all 
components of the drug product were known, it was decided to determine the accuracy of 
the  method by using the standard addition  method.  The sample  was assayed,  known 
amounts of active ingredients were added and the spiked solutions were assayed again. 
Accuracy was then established by calculating the recovery, which is defined as the ratio 
of  the  observed  result  to  the  expected  result  expressed  as  a  percentage. Nine 
determinations at three different concentration levels were carried out.
46
It was decided to spike sample solutions with a concentration of 0.2 mg EFV, 66.7 µg 
FTC and 0.1 mg TDF per ml, which corresponds to 100% of the test concentration, with 
drug substances to obtain solutions with concentrations of 180%, 200% and 220% of the 
test  concentration.  Therefore a  sample  solution with a  concentration  of  0.4 mg EFV, 
133.4 µg FTC and 0.2 mg TDF per ml in MeOH:H2O, 50:50 (v/v) was prepared. A drug 
substance solution containing 0.48 mg EFV, 160.08 µg FTC and 0.24 mg TDF per ml 
was prepared and further diluted to also obtain concentrations corresponding to 200% and 
160% of the test concentration. The sample solution was then in turn mixed 50:50 with 
the  drug substance  solutions  to  obtain  concentrations  equivalent  to  220%, 200% and 
180% of the test solution corresponding to an addition of 120, 100 and 80% respectively.  
The solutions were analyzed in triplicate and the average content of EFV, FTC and TDF 
was calculated using a drug substance solution with a concentration of 0.2 mg EFV, 66.7 
µg FTC and 0.1 mg TDF per ml as a reference. The amount of EFV, FTC and TDF in the 
unspiked sample solution was determined and used to calculate recovery for the spiked 
solution with the formula:
R = a *100 / b
with R: recovery
a: observed result
b: expected result
Table 9: Findings for accuracy of the assay method for EFV/FTC/TDF tablets - part 1
Recovery (%)
Spike solution EFV FTC TDF
80% 93.5 101.5 95.0
100% 93.9 101.7 93.9
120% 93.7 101.0 92.0
However, the results do not meet the limits given in literature, which states that dosage 
form assays usually provide accuracy within 3-5% of the true value, and due to the fact 
that  the  recovery  is  worse  for  spiked  solutions  with  higher  concentrations  it  was 
concluded that there might be some solubility problems. As a next step, solutions with 
lower concentrations were used.
A sample solution with a concentration of 0.2 mg EFV, 66.7 µg FTC and 0.1 mg TDF per 
ml in MeOH:H2O, 50:50 (v/v) was prepared. A drug substance solution containing 0.28 
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mg EFV, 93.38 µg FTC and 0.14 mg TDF per ml was prepared and further diluted to also 
obtain  concentrations  corresponding to  100% and 60% of the test  concentration.  The 
sample solution was then in turn mixed 50:50 with the drug substance solutions to obtain 
concentrations equivalent to 120%, 100% and 80% of the test solution.  The solutions 
were analyzed in triplicate and the average content of EFV, FTC and TDF was calculated 
using a drug substance solution with a concentration of 0.2 mg EFV, 66.7 µg FTC and 
0.1 mg TDF per ml as a reference. The amount of EFV, FTC and TDF in the unspiked 
sample solution was determined and used to calculate recovery for the spiked solution by 
using the formula given above.
Table 10: Findings for accuracy of the assay method for EFV/FTC/TDF tablets - part 2
Recovery
Spike solution EFV FTC TDF
80% 102.1 98.9 100.3
100% 101.3 99.1 99.9
120% 100.3 98.7 98.9
As can be seen from the results compiled in Tables 9 and 10, the second approach clearly 
meets the requirements. It was therefore concluded that the unsatisfactory results with the 
more highly concentrated solutions were due to solubility problems and the accuracy of 
the method is good.
3.2.1.5 Range
The range was established from 80 to 120% of the test  concentration (EFV 160-240 
μg/ml,  FTC 53-80  μg/ml,  TDF 80-120  μg/ml) by proving that linearity,  precision and 
accuracy of the assay within these limits are good.
3.2.1.6 Evaluation of different stationary phases for selectivity
No tests  for robustness were carried out,  as the resolution between the peaks is high 
enough to presume that the reliability of the method is not susceptible to minor variations 
in method parameters. However, the method was tested using different columns to verify 
the applicability. For this purpose, the database of the column classification system for 
HPLC columns developed by our laboratory was used to find columns similar to the one 
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used [Column Classification System]. The five most similar were identified by their F-
values.  The  lower  the  F-value,  the  higher  the  similarity  to  the  column  selected  as 
reference, which was in our case the column used for method development. These five 
columns were:
1. Brava BDS 5, 250 x 4.6 mm I.D., 5µm (F = 0.152)
2. HyPurity Elite C18, 150 x 4.6 mm I.D., 3 µm (F = 0.330)
3. HyPurity C18, 250 x 4.6 mm I.D., 5 µm (F = 0.343)
4. HyPurity Elite C18, 150 x 4.6 mm I.D., 5 µm (F = 0.357)
5. Discovery C18, 250 x 4.6 mm I.D., 5 µm (F = 0.404)
As described in the monograph, a sample solution containing 0.2 mg EFV, 66.7 µg FTC 
and 0.1 mg TDF per ml in MeOH:H2O, 50:50 (v/v) was prepared and analyzed on each of 
these columns. The resulting chromatograms are given in Figure 19.
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 (d) 
Figure 18: Chromatograms for separation of EFV/FTC/TDF tablets obtained on different columns, (a)  
Brava BDS (250 x 4.6 mm I.D., 5 µm, F = 0.152), (b) HyPurity Elite (150 x 4.6 mm I.D., 3 µm, F = 0.330),  
(c) HyPurity (250 x 4.6 mm I.D., 5 µm, F = 0.343), (d) HyPurity Elite (150 x 4.6 mm I.D., 5 µm, F = 0.357)  
and (e) Discovery (250 x 4.6 mm I.D., 5 µm, F = 0.404). 
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These columns give similar results as the reference column but for some of them the 
fumarate peak coelutes with a solvent peak.
3.2.2 FTC/TDF tablets
The assay method extracted from the Ph. Int. monograph is given as follows:
Assay
Carry out the test as described under  1.14.4 High-performance liquid chromatography, 
using a stainless steel column (25 cm x 4.6 mm) packed with base-deactivated particles 
of  silica  gel  the  surface  of  which  has  been  modified  with  chemically  bonded 
octadecylsilyl groups (5 μm).
The mobile  phases  for  gradient  elution  consist  of  a  mixture  of  Mobile  phase A and 
Mobile phase B, using the following conditions:
Mobile phase A: 5 volumes of phosphate solution and 95 volumes of water R.
Mobile phase B: 70 volumes of acetonitrile R, 5 volumes of phosphate solution and 
25 volumes of water R.
Prepare the phosphate solution by dissolving 27.22 g of potassium dihydrogen phosphate 
R in 1000 ml of water R.
Table 11: Gradient programme for LC analysis of FTC/TDF tablets
Time
(min)
Mobile phase A
(% v/v)
Mobile phase B
(% v/v)
Comments
0 – 9 93 7 Isocratic
9 – 15 93 to 0 7 to 100 Linear gradient
15 – 19 0 100 Isocratic
19 – 19.1 0 to 93 100 to 7 Return to initial 
composition
19.1-30 93 7 Re-equilibration
After preparation, keep the solutions at about 6 °C, or use an injector with cooling.
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Prepare the following solutions, using a mixture of 20 volumes of acetonitrile R and 80 
volumes of water R as a diluent. For solution (1) weigh and powder 20 tablets. Disperse a 
quantity  of  the  powder  containing  about  10  mg  of  Tenofovir  disoproxil  fumarate, 
accurately weighed in 100 ml of the diluent and filter. For solution (2) dissolve quantities 
of  tenofovir  disoproxil  fumarate  RS  and emtricitabine  RS in  the  diluent  to  obtain  a 
concentration  of  0.1  mg/ml  and  66.7  µg/ml  of  tenofovir  disoproxil  fumarate  and 
emtricitabine, respectively. If necessary, adapt the concentration of solution (2) according 
to the ratio of Emtricitabine and Tenofovir disoproxil fumarate in the tablets. For solution 
(3) use 0.02 mg of fumaric acid R per ml of water R.
Operate  with  a  flow  rate  of  1.0  ml  per  minute.  As  a  detector  use  an  ultraviolet  
spectrophotometer set at a wavelength of 280 nm.
Maintain the column temperature at 35°C.
Inject alternatively 20 µl each of solutions (1), (2) and (3).
The test is not valid unless in the chromatograms obtained with solutions (1) and (2), 
three principal peaks are shown and the resolution factor between those peaks is at least 
5.
Measure the areas of the peak responses obtained in the chromatograms from solutions 
(1)  and  (2),  and  calculate  the  content  of  emtricitabine  (C8H10FN3O3S) and  tenofovir 
disoproxil fumarate (C19H30N5O10P,C4H4O4) in the tablets.
3.2.2.1 Sensitivity
LOQ values for EFV, FTC and TDF were 0.49%, 0.06% and 0.50% and LOD 0.15%, 
0.02% and 0.15%, respectively. The percentages were calculated with respect to the main 
component nominal value (200 µg/ml = 100% for EFV, 66.7 µg/ml = 100% for FTC and 
100 µg/ml = 100% for TDF, 20 µl injected).
3.2.2.2 Linearity
Linearity was established from 0.5 to 125% of the test concentration, using 5 different 
concentrations.  An FTC solution  and a  TDF solution  in  ACN:H2O, 20:80 (v/v)  with 
concentrations corresponding to 250% of the test concentration were prepared and then 
52
mixed 50:50 with the solvent to obtain a 125% solution. This was in turn diluted with the 
solvent  to  obtain  solutions  with  concentrations  of  100,  50,  5  and  0.5%  of  the  test 
concentration  (100  % =  66.7  µg/ml  FTC and  0.1  mg/ml  TDF).  The  solutions  were 
analyzed in triplicate, the average response for each solution was calculated and used to 
create a plot depicting the response as a function of concentration (Figure 19).
Table 12: Findings for linearity of the assay method for FTC/TDF tablets
FTC TDF
Concentration
(µg/ml)
0.33-83.3 0.5-125
Coefficient of determination 
(R²)
0.9999 0.9995
Regression equation y = 454.32x + 127.05 y =  68.111x + 57.565
As can be seen from Figure 19 and Table 12, the method is linear in the investigated 
range.
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Figure 19: Linearity of the assay method for FTC/TDF tablets
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3.2.2.3 Precision
Precision was determined by assessing repeatability and intermediate precision.
3.2.2.3.1 Repeatability
Repeatability was assessed by using six determinations at 100% of the test concentration. 
Therefore, a reference solution containing FTC and TDF with 100% of the nominal test 
concentration was prepared and injected six times,  as well  as a sample solution.  The 
sample solution was prepared, as described in the monograph, to obtain a concentration 
of  66.7  µg FTC and 0.1 mg TDF per  ml.  After  normalizing  the  response  areas,  the 
average content of FTC and TDF in the sample was calculated, and standard deviation 
and RSD were determined. The results are given in Table 13.
Table 13: Findings for repeatability of the assay method for FTC/TDF tablets
FTC TDF
Average content 100.1 99.6
Standard deviation 0.1 0.2
%RSD 0.1 0.2
As can be seen from Table 13, the RSD value for each component is not more than 0.2%, 
indicating the method is repeatable.
3.2.2.3.2 Intermediate Precision
Intermediate  precision  was  established  by  injecting  a  reference  solution  of  drug 
substances  with  a  concentration  of  100% of  the  nominal  test  concentration  and  the 
sample solution six times, over four days. The analyses of days 1 and 2 were carried out  
on LC-apparatus II, those of days 3 and 4 on LC-apparatus I and with a different column. 
After normalization, average content of FTC and TDF, standard deviation and RSD were 
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calculated for each day (Table 14). RSD was also determined for days 1+2, 3+4 and all 
four days (Table 15).
Table 14: Findings for intermediate precision of the assay method for FTC/TDF tablets
Day 1 Day 2 Day 3 Day 4
FTC TDF FTC TDF FTC TDF FTC TDF
Average content 100.7 99.6 101.3 102.0 98.6 97.6 98.0 97.4
Standard deviation 0.1 0.2 0.2 0.05 0.5 0.2 0.3 0.2
%RSD 0.1 0.2 0.2 0.05 0.5 0.2 0.3 0.2
Table 15: Summarized findings for intermediate precision of the assay method for FTC/TDF tablets
Days 1+2 Days 3+4 All 4 days
FTC TDF FTC TDF FTC TDF
%RSD 0.1 0.1 0.4 0.2 0.3 0.2
As can be seen from Tables 14 and 15, the RSD values for each component are not more 
than 0.5% indicating that the method is precise. 
3.2.2.4 Accuracy
Like for the triple combination,  accuracy was determined by spiking sample solutions 
with  known amounts  of  the  drug  substances.  Therefore  nine  determinations  at  three 
different concentration levels were carried out.
A sample  solution  with a  concentration  of  66.7 µg FTC and 0.1 mg TDF per ml  in 
ACN:H2O, 20:80 (v/v) was prepared. A drug substance solution containing 93.38 µg FTC 
and 0.14 mg TDF per ml was prepared and further diluted to also obtain concentrations 
corresponding to 100% and 60% of the test concentration. The sample solution was then 
in turn mixed 50:50 with the drug substance solutions to obtain concentrations equivalent 
to 120%, 100% and 80% of the test solution. The solutions were analyzed in triplicate  
and the average content of FTC and TDF was calculated using a drug substance solution 
with a concentration of 66.7 µg FTC and 0.1 mg TDF per ml as a reference. The amount 
of FTC and TDF in the unspiked sample solution was determined and used to calculate 
recovery for the spiked solution with the formula:
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R = a *100 / b
with R: recovery
a: observed result
b: expected result
Table 16: Findings for accuracy of the assay method for FTC/TDF tablets
Spike solution 80 % 100 % 120 %
Recovery (%)
FTC 98.2 98.7 99.4
TDF 98.8 98.3 98.3
The results for recovery indicate that the method is accurate.
3.2.2.5 Range
The range was established from 80 to 120% of the test concentration (FTC 53-80 μg/ml, 
TDF 80-120 μg/ml) by proving that linearity, precision and accuracy of the assay within 
these limits are good.
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4 Conclusion
A monograph for RTV tablets was developed for inclusion in the Ph. Int. It contains basic 
information and methods of analysis to verify identity and allow for the determination of 
related substances. A method for dissolution testing was established and quantification of 
samples is included. Although the Ph. Int. focuses on simple operations, that can easily be 
performed,  it  was  not  always  possible  to  meet  this  requirement  and LC methods are 
widely used . Simpler methods, which are used for analysis of RTV drug substance, were 
used to test the sample tablets, but were found to be not suitable for the dosage form.
A report of the proposed monograph has been submitted to the WHO and is open for 
discussion.  Future  work  has  to  be  done  to  check  the  universal  applicability  of  the 
methods,  as the piece of work was subject to some limitations.  The excipients of the 
tablets were not known, which made the work more complicated. It has to be pointed out 
that, due to the lack of availability, the whole development was based on one batch of 
sample tablets only.  Verifying the methods with different samples will therefore be of 
great importance.
For the validation of the monographs for EFV/FTC/TDF tablets and FTC/TDF tablets, 
the parameters of interest were identified and tests were carried out accordingly. Minor 
difficulties were encountered in the process, and small adjustments were made. The tests 
for  the  assay  methods  showed  good  results,  the  methods  are  very  suitable  for  the 
quantification of these fixed dosage combinations.
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5 Abstract
The human immunodeficiency virus (HIV) is a retrovirus that causes chronic infection 
and progressively destroys host immunities. This in turn leads to a weakened immune 
system  and  higher  risk  of  opportunistic  infections  called  acquired  immunodeficiency 
syndrome (AIDS). According to UNAIDS statistics, 60 million people have been infected 
with HIV since the beginning of the epidemic in the 1980s and 25  million people have 
died of HIV-related causes. This makes HIV one of the main health issues in the new 
millennium. 
97% of people with HIV live in low and middle income-countries and although there is a 
range  of  medicines  approved  for  treatment  of  HIV  infection,  the  coverage  of 
antiretroviral therapy in these countries is only 36%. One of the biggest challenges in 
fighting HIV is therefore providing antiretroviral medicines to those in need.
In  an  effort  to  improve  the  overall  quality  of,  not  only  antiretroviral  medicines,  the 
International Pharmacopoeia provides information on pharmaceutical specifications and 
methods of analysis. It also includes monographs on antiretroviral medicines, and dosage 
forms.
In this  work  a  monograph for ritonavir  tablets  has  been developed and proposed for 
inclusion  in  the  International  Pharmacopoeia. Furthermore,  two  assay  methods  of 
proposed  monographs  for  fixed  dosage  combinations  of  efavirenz,  emtricitabine  and 
tenofovir disoproxil fumarate as well as emtricitabine and tenofovir disoproxil fumarate 
were validated.
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6 Zusammenfassung
Das Humane Immundefizienz Virus (HIV) ist ein Retrovirus, das chronische Infektionen 
verursacht und dabei in fortschreitendem Maße das Immunsystem des Wirtes zerstört. 
Durch  diese  Schwächung  der  Immunabwehr  kommt  es  zu  einer  Häufung  von 
opportunistischen Infektionen und einer  generellen  schlechten  Immunlage,  welche  als 
acquired  immunodeficiency  syndrome  (AIDS)  bezeichnet  wird.  Laut  UNAIDS 
Schätzungen  infizierten  sich  seit  Beginn  der  Epidemie  Mitte  der  1980er  Jahre  60 
Millionen Menschen mit HIV und 25 Millionen Menschen kamen durch HIV-assoziierte 
Komplikationen  zu  Tode.  HIV  stellt  damit  eine  der  größten  Herausforderungen  im 
Gesundheitswesen im neuen Millennium dar.
97  Prozent  der  HIV-Erkrankten  leben  in  einkommensschwachen  Ländern  und 
Schwellenländern.  Trotz  der  vorhandenen  Auswahl  an  antiretroviralen  Arzneistoffen 
beträgt  die  Behandlungsquote  in  diesen  Staaten  nur  36  Prozent.  Eine  der  größten 
Herausforderungen im Kampf gegen HIV ist somit die Bereitstellung von antiretroviralen 
Arzneimitteln für jene, die sie benötigen.
Die Internationale Pharmacopöe ist ein Ansatz, um die Qualität von pharmazeutischen 
Produkten, unter anderem auch antitetroviralen Medikamenten, zu verbessern, und bietet 
Informationen  zu  Anforderungen und Qualitätsstandards  sowie  Analysemethoden.  Sie 
enthält  Monographien  zu  Arzneistoffen  und  Darreichungsformen  unterschiedlicher 
Anwendungsgebiete.
In  dieser  Arbeit  wird  die  Ausarbeitung  einer  Monographie  für  Ritonavir  Tabletten 
beschrieben  und  der  Monographievorschlag  vorgestellt.  Darüber  hinaus  wurden  zwei 
assay-Methoden  für  Kombinationspräparate,  die  Efavirenz,  Emtricitabin  und 
Tenofovirdisoproxilfumarat bzw. Emtricitabin und Tenofovirdisoproxilfumarat enthalten, 
validiert.
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